Dr. Temel on Anorexia and Cachexia in NSCLC

Jennifer Temel, MD
Published: Monday, Jul 13, 2015



Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.

The drug was shown to improve muscle mass and facilitate weight gain in NSCLC patients with anorexia and cachexia, said Temel.

Cancer anorexia and cachexia are common amongst patients with advanced cancer. Currently, therapeutic options are limited, so the potential of anamorelin is exciting, said Temel.



Jennifer Temel, MD, Associate Professor, Medicine, Harvard Medical School Clinical Director, Thoracic Oncology, Massachusetts General Hospital, and Associate Director, Hematology/Oncology Fellowship Program, Dana-Farber, discusses a phase III study assessing the impact of anamorelin on body weight, lean body mass, and appetite in advanced non-small cell lung cancer (NSCLC) patients with anorexia and cachexia.

The drug was shown to improve muscle mass and facilitate weight gain in NSCLC patients with anorexia and cachexia, said Temel.

Cancer anorexia and cachexia are common amongst patients with advanced cancer. Currently, therapeutic options are limited, so the potential of anamorelin is exciting, said Temel.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x